WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has received U.S. Food and Drug Administration authorization for rolling review of its New Drug Application for QTORIN rapamycin, a step that could accelerate regulatory evaluation of what may become the first approved treatment for patients with microcystic lymphatic malformations, a rare and progressive disease with no FDA-approved therapies.
The clinical-stage biotechnology company reported that the FDA granted rolling review based on QTORIN’s Fast Track and Breakthrough Therapy designations. The company expects to complete submission of the application during the second half of 2026.
Rolling review allows drug developers to submit completed portions of an application before the full package is finalized, enabling FDA reviewers to begin evaluating data while additional sections are prepared.
The regulatory milestone follows positive Phase 3 results from Palvella’s SELVA trial and represents another step toward potential commercialization of the therapy.
“We remain on track to complete submission of the QTORIN rapamycin NDA in the second half of 2026 and intend to utilize the benefits of rolling review, Breakthrough Therapy and Fast Track designations to support an efficient path toward potential approval,” Chief Executive Officer Wes Kaupinen stated.
Microcystic lymphatic malformations are rare genetic disorders caused by dysregulation of the PI3K/mTOR signaling pathway. The condition can result in malformed lymphatic vessels that protrude through the skin, causing chronic leakage, bleeding, recurrent infections, cellulitis and, in some cases, hospitalization.
According to Palvella, published natural history data indicate the disease is persistent and progressive and does not resolve spontaneously. Current management options, including surgery, sclerotherapy and laser treatment, can be limited by recurrence and the need for repeated procedures.
The company estimates that more than 30,000 people in the United States have been diagnosed with microcystic lymphatic malformations.
Palvella indicated that QTORIN is designed to deliver rapamycin directly to affected skin tissue to inhibit disease-driving mTOR signaling while limiting systemic exposure. The approach is intended to address concerns associated with long-term use of systemic PI3K/mTOR inhibitors, particularly in pediatric patients.
QTORIN has previously received Breakthrough Therapy, Fast Track and Orphan Drug designations from the FDA for the treatment of microcystic lymphatic malformations.
If approved, the therapy would establish Palvella’s first commercial product and provide the first FDA-approved treatment option for patients living with the rare disorder.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.